New Blood Test Could Make Measuring Advanced Alzheimer’s Disease More Accessible

Researchers have developed a new immunoassay blood test that can detect advanced Alzheimer's disease by measuring the eMTBR-tau biomarker. This method offers a more accessible alternative to specialized mass spectrometry, potentially improving the diagnosis of disease severity and cognitive decline.
Why it matters
Improving the accessibility of Alzheimer's diagnostics is critical for early intervention and managing the global burden of neurodegenerative diseases.
Researchers have developed a new blood test that could make it easier to assess advanced Alzheimer’s disease, using a simpler laboratory method to measure a biomarker previously detectable only with specialized mass spectrometry.
The test measures eMTBR-tau, a fragment of tau protein that earlier studies linked to the accumulation of neurofibrillary tangles in the brain. Unlike existing blood tests that primarily identify earlier Alzheimer’s-related changes, eMTBR-tau may provide information about more advanced pathology associated with cognitive decline.
In a study of 728 participants published in JAMA , researchers at Banner Sun Health Research Institute in Arizona, Lund University in Sweden, and collaborating institutions found that the new immunoassay accurately identified advanced tau pathology, with performance comparable to mass spectrometry. The assay was developed in collaboration with Alamar Biosciences.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in